These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1201 related items for PubMed ID: 20531012

  • 1. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH.
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Does mirtazapine have a more rapid onset than SSRIs?
    Quitkin FM, Taylor BP, Kremer C.
    J Clin Psychiatry; 2001 May; 62(5):358-61. PubMed ID: 11411818
    [Abstract] [Full Text] [Related]

  • 4. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C.
    J Clin Psychiatry; 1999 May; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [Abstract] [Full Text] [Related]

  • 5. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.
    Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA, Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group.
    J Clin Psychiatry; 2008 Sep; 69(9):1404-15. PubMed ID: 19193341
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
    Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME.
    Biol Psychiatry; 2008 Feb 15; 63(4):424-34. PubMed ID: 17888885
    [Abstract] [Full Text] [Related]

  • 7. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
    Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH.
    Am J Psychiatry; 2016 Feb 01; 173(2):174-83. PubMed ID: 26552940
    [Abstract] [Full Text] [Related]

  • 8. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
    Pallanti S, Quercioli L, Bruscoli M.
    J Clin Psychiatry; 2004 Oct 01; 65(10):1394-9. PubMed ID: 15491244
    [Abstract] [Full Text] [Related]

  • 9. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
    Papakostas GI, Charles D, Fava M.
    World J Biol Psychiatry; 2010 Mar 01; 11(2 Pt 2):300-7. PubMed ID: 20218793
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.
    Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M.
    J Clin Psychiatry; 2001 Jun 01; 62(6):413-20. PubMed ID: 11465517
    [Abstract] [Full Text] [Related]

  • 11. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ, CO-MED Study Team.
    J Clin Psychiatry; 2012 Jul 01; 73(7):967-76. PubMed ID: 22687487
    [Abstract] [Full Text] [Related]

  • 12. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
    Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N.
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr 01; 259(3):172-85. PubMed ID: 19165525
    [Abstract] [Full Text] [Related]

  • 13. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
    Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O.
    J Clin Psychiatry; 2003 Apr 01; 64(4):413-20. PubMed ID: 12716243
    [Abstract] [Full Text] [Related]

  • 14. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.
    Kato M, Takekita Y, Koshikawa Y, Sakai S, Bandou H, Nishida K, Sunada N, Onohara A, Hatashita Y, Serretti A, Kinoshita T.
    J Psychiatr Res; 2017 Jun 01; 89():97-104. PubMed ID: 28213170
    [Abstract] [Full Text] [Related]

  • 15. Care of depressed patients with anxiety symptoms.
    Nutt DJ.
    J Clin Psychiatry; 1999 Jun 01; 60 Suppl 17():23-7; discussion 46-8. PubMed ID: 10446738
    [Abstract] [Full Text] [Related]

  • 16. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
    Papakostas GI, Homberger CH, Fava M.
    J Psychopharmacol; 2008 Nov 01; 22(8):843-8. PubMed ID: 18308801
    [Abstract] [Full Text] [Related]

  • 17. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.
    Arch Gen Psychiatry; 2004 Nov 01; 61(11):1163-9. PubMed ID: 15520364
    [Abstract] [Full Text] [Related]

  • 18. Mirtazapine. A pharmacoeconomic review of its use in depression.
    Holm KJ, Jarvis B, Foster RH.
    Pharmacoeconomics; 2000 May 01; 17(5):515-34. PubMed ID: 10977391
    [Abstract] [Full Text] [Related]

  • 19. Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol.
    Furukawa TA, Akechi T, Shimodera S, Yamada M, Miki K, Watanabe N, Inagaki M, Yonemoto N.
    Trials; 2011 May 11; 12():116. PubMed ID: 21569309
    [Abstract] [Full Text] [Related]

  • 20. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
    Hieronymus F, Lisinski A, Nilsson S, Eriksson E.
    Lancet Psychiatry; 2019 Sep 11; 6(9):745-752. PubMed ID: 31303567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.